Search

Background: Babesia microti has gained a foothold in Canada as tick vectors become established in broader geographic areas. B. microti infection is associated with mild or no symptoms in healthy individuals but is transfusion‐transmissible and can be fatal in immunocompromised individuals. This is the first estimate of clinically significant transfusion‐transmitted babesiosis (TTB) risk in Canada. Study design and methods: The proportion of B. microti‐antibody (AB)/nucleic acid amplification test (NAT)‐positive whole blood donations was estimated at 5.5% of the proportion of the general population with reported Lyme Disease (also tick‐borne) based on US data. Monte Carlo simulation estimated the number and proportion of infectious red cell units for three scenarios: base, localized incidence (risk in Manitoba only), and donor study informed (prevalence from donor data). The model simulated 1,029,800 donations repeated 100,000 times for each. Results: In the base scenario 0.5 (0.01, 1.75), B. microti‐NAT‐positive donations would be expected per year, with 0.08 (0, 0.38) recipients suffering clinically significant TTB (1 every 12.5 years). In the localized incidence scenario, there were 0.21(0, 0.7) B. microti‐NAT‐positive donations, with 0.04 (0, 0.14) recipient infections (about 1 every 25 years). In the donor study informed scenario, there were 4.6 (0.3, 15.8) B. microti‐NAT‐positive donations expected, and 0.81 (0.05, 3.14) clinically significant TTB cases per year. Discussion The likelihood of clinically relevant TTB is low. Testing would have very little utility in Canada at this time. Ongoing pathogen surveillance in tick vectors is important as B. microti prevalence appears to be slowly increasing in Canada. [ABSTRACT FROM AUTHOR]